XK and influenza: In summary, this work demonstrates that bivalent vaccines using sa-mRNA technology induce robust neutralizing and protective anti-influenza adaptive immune responses in vivo against both HA and NA, and these bivalent constructs can be co-formulated in a quadrivalent vaccine against four seasonal influenza strains, generating immunity to eight viral antigens simultaneously.